Objective-Neuropilin-1 (NRP-1) is a multidomain membrane receptor involved in angiogenesis and development of neuronal circuits, however, the role of NRP-1 in cardiovascular pathophysiology remains elusive. Approach and Results-In this study, we first observed that deletion of NRP-1 induced peroxisome proliferator-activated receptor γ coactivator 1α in cardiomyocytes and vascular smooth muscle cells, which was accompanied by dysregulated cardiac mitochondrial accumulation and induction of cardiac hypertrophy-and stress-related markers. To investigate the role of NRP-1 in vivo, we generated mice lacking Nrp-1 in cardiomyocytes and vascular smooth muscle cells (SM22-α-Nrp-1 KO), which exhibited decreased survival rates, developed cardiomyopathy, and aggravated ischemia-induced heart failure. Mechanistically, we found that NRP-1 specifically controls peroxisome proliferator-activated receptor γ coactivator 1 α and peroxisome proliferator-activated receptor γ in cardiomyocytes through crosstalk with Notch1 and Smad2 signaling pathways, respectively. Moreover, SM22-α-Nrp-1 KO mice exhibited impaired physical activities and altered metabolite levels in serum, liver, and adipose tissues, as demonstrated by global metabolic profiling analysis. Conclusions-Our findings provide new insights into the cardioprotective role of NRP-1 and its influence on global metabolism.
N europilin-1 (NRP-1) is a multidomain receptor with functional roles in the cardiovascular system and involvement in neuronal development and the pathogenesis of cancer. [1] [2] [3] Currently, it is known that NRP-1 binds several structurally diverse ligands and mediates different cellular functions, including endothelial chemotaxis, cell adhesion, axon guidance, and participation in multiple signal transduction pathways. 4, 5 Global Nrp-1 null mice die midway through gestation (E12.5-E13.5) and demonstrate abnormalities in the cardiovascular and nervous systems. 6, 7 In addition, mice lacking the genes encoding various NRP-1 ligands, including vascular endothelial growth factor-A (VEGF-A), VEGF-B, placenta growth factor-2, semaphorin-3A, semaphorin-3C, plateletderived growth factor, and transforming growth factor-β (TGFβ), showed diverse cardiovascular defects. 6, [8] [9] [10] In the cardiovascular system, NRP-1 is highly expressed in endothelial cells, vascular smooth muscle cells (VSMCs), and cardiomyocytes. [11] [12] [13] Conditional deletion of NRP-1 in endothelial cells through the use of Tie2-Cre transgenic mice resulted in mid-to-late embryonic lethality and replicated several of the cardiovascular defects seen in the global Nrp-1 knockout. These defects include a general peripheral vascular branching deficiency and a failure to septate the outflow tract of the heart. 14 To date, the precise function of NRP-1 in cardiomyocytes and VSMCs and its role in mediating cardiovascular pathophysiology have not been characterized. In this study, our results showed that deletion of NRP-1 elevated peroxisome proliferator-activated receptor γ coactivator 1 α (PGC1α) in cardiomyocytes and VSMCs, induced expression of cardiac hypertrophy, stress-related markers, and abnormal cardiac mitochondrial accumulation, suggesting NRP-1 is involved in the pathogenesis of cardiac diseases. We generated a cell type-specific knockout of NRP-1 in cardiomyocytes and VSMCs by crossing Nrp-1 flox/flox mice 2 with the SM22-α-Cre transgenic mice. 15 The SM22-α promoter is highly efficient in mediating recombination in cardiomyocytes and VSMCs in contrast to the smooth muscle myosin heavy chain (MHC) promoter. 16 For these studies, we used 2 genotypes: SM22-α-Cre negative Nrp-1 flox/flox designated as wild-type (WT) and SM22-α-Cre positive Nrp-1 flox/flox designated as the SM22-α-Nrp-1 KO. Knockout of NRP-1 in cardiomyocytes and VSMCs decreased survival rates, led to cardiomyopathy, and caused the SM22-α-Nrp-1 KO mice to be prone to heart failure after myocardial infarction (MI). On exploring the molecular mechanism of this deleterious effect, we found that regulation of PGC1α and peroxisome proliferator-activated receptor γ (PPARγ) occurs through crosstalk of NRP-1 with Notch1 and Smad2 pathways. Moreover, knockout of NRP-1 in cardiomyocytes and VSMCs caused impaired physical activities and aberrant global metabolism. Our findings suggest that the expression of NRP-1 in cardiomyocytes and VSMCs provides a protective effect under basal conditions and during ischemic stress and contributes to global metabolism.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

NRP-1 Regulates PGC1α in Cardiomyocytes and VSMCs
To investigate the role of NRP-1 in cardiomyocytes and VSMCs, we first introduced adenovirus Cre to cardiomyocytes and VSMCs isolated from NRP-1 f/f mice to generate NRP-1 null cardiomyocytes and VSMCs in vitro. As shown in Figure 1A -1C, we observed that deletion of NRP-1 significantly elevated expression of PGC1α, the key regulator of mitochondrial biogenesis, 17 in cardiomyocytes and VSMCs. Accompanied with increased expression of PGC1α, its downstream effectors, including medium-chain acyl-CoA dehydrogenase, citrate synthase, ATP synthase C, cytochrome C, and mitochondrial transcription factor B2M, were also significantly increased in NRP-1 KO cardiomyocytes ( Figure 1D and 1E). Meanwhile, cardiac hypertrophy and stress markers, such as brain natriuretic peptide, atrial natriuretic factor, βMHC, and c-Myc, were induced in NRP-1 null cardiomyocytes ( Figure 1F ). These results suggest that NRP-1 is involved in regulation of PGC1α in cardiomyocytes and VSMCs, and a basal level of NRP-1 is essential to maintain homeostasis of cardiomyocytes.
To further investigate the role of NRP-1 in cardiomyocytes and VSMCs in vivo, we generated conditional knockout mice by crossing Nrp-1 flox/flox mice with SM22-α-Cre mice. Unlike the endothelial cell-specific Nrp-1 knockout mice, which die soon after birth, the SM22-α-Nrp-1 KO mice are viable. The efficiency of Cre-mediated recombination was confirmed with robust and specific X-gal staining in the hearts and aortas of SM22-α-ROSA26 mice ( Figure IA Elevated levels of PPARγ together with its downstream target carnitine palmitoyltransferase 1B were also observed in NRP-1 deleted cardiomyocytes ( Figure 1H ; Figure IIA and IID in the online-only Data Supplement). Immunofluorescent and immunohistochemical staining further confirmed increased PGC1α and PPARγ in adult heart tissues from SM22-α-Nrp-1 KO mice ( Figure IIB and IIC in the onlineonly Data Supplement). Accompanied with increased expression of PGC1α, elevated mitochondrial DNA copy number was present in neonatal cardiomyocytes isolated from SM22-α-Nrp-1 KO mice ( Figure 1I ). Correspondingly, NRP-1 knockout fibroblasts exhibited significantly increased mitochondrial oxygen consumption under different respiratory conditions ( Figure 1J ). Meanwhile, metabolites analysis showed increased trends of metabolites of tricarboxylic acid cycle in cardiac tissues from SM22-α-Nrp-1 KO mice ( Figure  III in the online-only Data Supplement). Electron microscopy further confirmed the presence of increased deposition of mitochondria and disorganized sarcomeres in hearts of 1-year-old SM22-α-Nrp-1 KO mice ( Figure 1K ; Figure  IIE in the online-only Data Supplement), which also showed significantly increased expression of brain natriuretic peptide together with increased trends of atrial natriuretic factor and c-Myc ( Figure 1L ). Furthermore, a prospective study for mortality was conducted to investigate the overall effect of deletion of NRP-1 in cardiomyocytes and SMCs. As shown in Figure 1M , whereas no significant mortality was observed in the WT group until 600 days old, the survival rate of SM22-α-Nrp-1 KO mice progressively declined. By 663 days of age, one third of the SM22-α-Nrp-1 KO mice died, whereas >85% of the WT mice remained alive.
Taken together, our results demonstrate that knockout of NRP-1 increased PGC1α and PPARγ expression in cardiomyocytes and SMCs and led to decreased survival rate accompanied with abnormal mitochondrial accumulation and induction of hypertrophy and stress-related markers in cardiomyocytes. f/f mice and infected with adenovirus Cre or adenovirus GFP as control. G, Frozen heart sections of wild-type (WT) and SM22-α-Nrp-1 KO mice were stained with antibodies against NRP-1 (red) and α-myosin heavy chain (MHC; green). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Results are representative of 3 independent experiments. H, qPCR was performed in neonatal CMs of WT mice and SM22-α-Nrp-1 KO mice. I, Total cellular DNA was extracted from neonatal CMs of control mice and SM22-α-Nrp-1 KO mice. Mitochondrial cytochrome oxidase 1 and lipoprotein lipase were analyzed with qPCR and expressed as a ratio of mitochondrial DNA (mtDNA) and nuclear DNA. J, Oxygen consumption of control and Nrp-1 KO mouse embryonic fibroblasts (MEFs) was measured using O2k oxygraph. ROUNTINE (basal oxygen consumption) was measured with normal serum-free culture medium. LEAK respiration was measured after oligomycin-induced inhibition of ATP synthesis. Electron transfer system (ETS) was measured with the addition of FCCP. n=3 for each group. K, Heart tissues of 1-year-old WT mice and SM22-α-Nrp-1 KO mice were subjected to transmission electron microscopy. Mitochondrial area was measured and analyzed. Results are representative from 10 sections of 1 heart each group. L, qPCR was performed with heart tissues of WT mice and SM22-α-Nrp-1 KO mice. n=3 for each group. M, Kaplan-Meier survival curves of WT mice and SM22-α-Nrp-1 KO mice. In (A and C-F), the ad GFP group was normalized to 1, and the ad Cre group was expressed as relative fold of control group. *P<0.05, **P<0.01, ***P<0.001 compared with control group. ANF indicates atrial natriuretic factor; BNP, brain natriuretic peptide; MCAD, medium-chain acyl-CoA dehydrogenase; PPARγ, peroxisome proliferator-activated receptor γ; and TFB2M, transcription factor B1M. June 2015
Cardiomyopathy in SM22-α-Nrp-1 KO Mice
Accompanied with the induction of cardiac hypertrophic markers, the SM22-α-Nrp-1 KO mice exhibited progressive hypertrophy of right ventricles (Figure 2A-2C ; Figure IVA in the online-only Data Supplement). Specifically, at 3 and 12 weeks old, SM22-α-Nrp-1 KO mice showed a hypertrophic right ventricle, whereas at 8 months old and 1 year old, SM22-α-Nrp-1 KO mice displayed a dilated right ventricle (Figure 2A-2C ). The mean cross-sectional area of cardiomyocytes was increased in the right ventricle of SM22-α-Nrp-1 KO mice at 3 weeks old ( Figure 2D ). More apoptotic cells were also noted in SM22-α-Nrp-1 KO mice at the age of 3 weeks old ( Figure 2E ). However, no histological signs of fibrosis were observed in SM22-α-Nrp-1 KO mice as shown by Masson's Trichrome staining in Figure 2B .
M-mode/2-dimensional (2D)/3D echocardiography was performed to examine cardiac function. As shown in Figure 3 Figure 3C , 3F, and 3H), suggesting that even though the ejection fraction was normal, the total volume of blood ejected by left ventricle at the systolic stage was decreased in SM22-α-Nrp-1 KO mice. This result was further supported by the decreased blood pressure observed in SM22-α-Nrp-1 KO mice, which showed normal structures of mesenteric arteries but had notably decreased systolic/diastolic blood pressures at the ages of both 3 weeks and 8 months ( Figure 3K ; Figure  IVB in the online-only Data Supplement).These results confirm that hypertrophic right ventricles and reduced cardiac output were present in SM22-α-Nrp-1 KO mice.
Because of the predominant change of the right ventricle in SM22-α-Nrp-1 KO mice, we also examined the lung structures Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Two hundred to 300 CMs were blindly counted per heart. n=7 for each group. E, Representative micrographs of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining of heart sections of WT mice and SM22-α-Nrp-1 KO mice at 3 weeks old. Nuclei were counterstained with DAPI. Total TUNEL positive cells were counted blindly per heart section. n=7 for each group. *P<0.05, ***P<0.001, compared with WT group. of both groups. As shown in Figure 3L , neither significant fibrosis nor abnormal vascular remodeling was observed in either group at 4 months and 8 months of age. However, perivascular inflammatory cell infiltration was observed in the lungs of 8-month-old SM22-α-Nrp-1 KO mice. Meanwhile, hemosiderin-laden macrophages were noticed in some 1-yearold SM22-α-Nrp-1 KO mice, suggesting the presence of cardiac dysfunction in 1-year-old NRP-1 KO mice ( Figure IVC in the online-only Data Supplement).
SM22-α-Nrp-1 KO Mice Showed Deleterious Effect in Ischemic Cardiomyopathy
To further investigate the role of NRP-1 in cardiac function, we produced MI in WT mice and SM22-α-Nrp-1 KO mice by permanent left anterior descending (LAD) coronary artery ligation at 12 weeks of age. As shown in the survival graph ( Figure 4A ), it was observed that survival for WT-MI mice dropped from 100% to 60% on postoperative day 3 and remained at 46.66% up to postoperative day 30, the end point of the experiment. In contrast, the SM22-α-Nrp-1 KO-MI group showed a dramatic and abrupt drop in survival after LAD ligation, from 100.00% to 38.46% on postoperative day 3, with no survivors past postoperative day 21.
Echocardiographic analysis performed preoperatively to assess the baseline function did not show any significant differences in systolic function of left ventricles between WT and SM22-α-Nrp-1 KO groups (Figure VA in the online-only Data Supplement). However, the ejection fraction and fractional shortening were significantly lower in SM22-α-Nrp-1 KO mice from as early as 3 days after MI ( Figure 4B ). As To evaluate the potential cause of the increased mortality rate and heart failure after permanent LAD ligation in the SM22-α-Nrp-1 KO mice, we evaluated 3 different heart tissues (unaffected myocardium, myocardium at the ischemic interface, and myocardium within the infarcted muscle) at 5 days post LAD ligation ( Figure 4C Figure 4C ). Hearts harvested from SM22-α-Nrp-1 KO mice had severely dilated vessels and extravascular hemorrhage in the inflammatory zone ( Figure 4C ). These findings demonstrate that knockout of NRP-1 in cardiomyocytes and VSMCs aggravated ischemia-induced heart failure.
Involvement of Smad2 and Notch1 in NRP-1-Mediated Regulation of PPARγ and PGC1α
To further delineate the upstream signaling of NRP-1 to PPARγ and PGC1α, the effect of several NRP-1 ligands on PPARγ was examined. As shown in Figure VIA in the onlineonly Data Supplement, TGFβ, but not other ligands of NRP-1, such as VEGF-A or platelet-derived growth factor-BB, downregulated PPARγ mRNA levels in mouse embryonic fibroblasts (MEFs). Using NRP-1 KO MEFs, we showed that knockout of NRP-1 partially restored the TGFβ-induced decrease of PPARγ and PGC1α expression (Figures 5A and  5B) . Our results suggest that NRP-1-dependent signaling is involved in the TGFβ-mediated downregulation of PPARγ and PGC1α mRNA expression.
Our previous studies have shown that knockdown of NRP-1 attenuated TGFβ-induced phosphorylation of Smad2/3, 18 so we examined activation of Smad2/3 in NRP-1 deleted cardiomyocytes and cardiac tissues. As shown in Figure 5C and Figure Figure 5D ), suggesting multiple mechanisms, including nuclear translocation of PPARγ, are involved in Smad2-mediated regulation of PPARγ regulation. Furthermore, overexpression of Smad2 partially rescued the expression of PPARγ but not PGC1α in NRP-1 deleted cardiomyocytes ( Figure 5F ), suggesting a different mechanism was involved in the regulation of PGC1α. Then, we examined the effect of NRP-1 on Notch1 in cardiomyocytes, which was reported recently to control PGC1α expression in adipocytes. 19 As shown in Figure 5G , intracellular domain of Notch1 was significantly reduced in NRP-1 knockout cardiomyocytes. Moreover, overexpression of intracellular domain of Notch1 partially recovered the PGC1α protein level in NRP-1 deleted cardiomyocytes ( Figure 5H ). Taken together, our results suggest that multiple downstream signaling pathways of NRP-1 synergize to regulate PGC1α and PPARγ.
Decreased Cardiorespiratory Fitness in SM22-α-Nrp-1 KO Mice
To evaluate the effect of NRP-1 knockout in cardiomyocytes and SMCs on cardiorespiratory fitness, we performed a high-precision indirect calorimeter in SM22-α-Nrp-1 KO mice. Our results showed that the SM22-α-Nrp-1 KO and WT mice had similar oxygen consumption and energy expenditure (Table 1 ). In contrast, the WT mice exhibited greater baseline physical activity (horizontal, vertical, ambulatory, and total activity counts) compared with the SM22-α-Nrp-1 KO mice (Table 2 ). In fact, the SM22-α-Nrp-1 KO mice appeared to have a severe impairment of all types of activity during both day and night light cycles. Considering that total energy expenditure and heat production were similar between the 2 phenotypes, the findings indicate that SM22-α-Nrp-1 KO mice have either a higher basal metabolic rate or reduced physical activity. In this regard, we proposed that the latter may result from cardiovascular limitations, and NRP-1 deficiency in cardiomyocytes and VSMCs leads to a significant deconditioning and impairment in ambulation. 
Metabolic Changes in SM22-α-Nrp-1 KO Mice
Previous studies have shown that metabolism in heart contributes to systemic metabolic homeostasis. 20 To evaluate the effect of NRP-1 deficiency in cardiomyocytes and VSMCs on whole body metabolism, we examined the metabolic phenotype of SM22-α-Nrp-1 KO mice. Global metabolite profiles in serum, adipose tissue, and livers were analyzed in mice fed a normal diet. Metabolomic profiles obtained from SM22-α-Nrp-1 KO mice and controls are summarized in Table 3 . Based on a targeted metabolomics approach, a total of 305 compounds of known identity (named biochemicals) were detected and quantified in serum, livers, and adipose tissues ( Table I in 
Discussion
Our results established, for the first time, the protective role of NRP-1 signaling in mitochondrial homeostasis of cardiomyocytes. Previous studies have shown that mitochondrial dysfunction and reduced ATP production are associated and accelerate the progressive nature of heart failure. 22, 23 Modulation of mitochondrial function reduces the infarct size of the ischemic heart in mice and represents a promising therapeutic strategy for heart failure. [24] [25] [26] In this context, our findings suggest that loss of NRP-1 in cardiomyocytes results in significant alterations in mitochondrial homeostasis, which may be because of altered PGC1α and PPARγ expression and eventually lead to cardiomyopathy and increased heart failure after ischemic stress.
Previous studies examining global Nrp-1 null mice 6, 7 and an endothelial-specific knockout of Nrp-1 showed extensive cardiovascular pathology.
14 However, neither of these studies examined cardiac NRP-1 function because of the developmental lethality in the null mice nor addressed any underlining mechanisms. Interestingly, 2 recent studies have shown that VEGF-B, a ligand of NRP-1, can control fatty acid transport through endothelial cells of heart and muscle 27 and inhibition of VEGF-B significantly improved the ectopic lipid deposition and insulin resistance in obese mice. 28 Although these studies suggest a potential role for NRP-1 in endothelial cells with respect to fatty acid transport, we did not observe significant downregulation of fatty acid transport protein (data not shown) or CD36 ( Figure II in the online-only Data Supplement) on NRP-1 knockout in cardiomyocytes or other nonendothelial cells. Therefore, the most likely role for NRP-1 in cardiomyocytes and in the VSMC compartments may not be consistent with endothelial cells as VEGF may be the main functional Animal was placed in chamber for measurement of 24-hour activity. Activities were monitored as described in Materials and Methods. Two-sided t test was performed. n=6 for each group. KO indicates SM22-α-Nrp-1 KO; RER, respiratory exchange ratio; and WT, wild-type. *P<0.05, and †P<0.001.
ligand in endothelium but in cardiomyocytes and VSMCs, TGFβ may be the key NRP-1 ligand of interest. Consistent with previous studies that reported NRP-1 acts as a coreceptor for TGFβ and mediates activation of the TGFβ-Smad2 pathway in fibroblasts, 18 cancer cells, 29 and T cells, 5 our results showed decreased phosphorylation of Smad2 in NRP-1 KO cardiomyocytes ( Figure 5 ; Figure VI in the online-only Data Supplement). Meanwhile, previous studies also demonstrated that the TGFβ pathway crosstalks with PPARγ in such a way that TGFβ downregulates PPARγ expression and its downstream effectors, [30] [31] [32] whereas PPARγ ligands counteracted TGFβ-mediated fibrosis 33 ; however, the crosstalk between TGFβ-Smad2 pathway and PPARγ remains unclear in cardiomyocytes. Our results showed that overexpression of Smad2 decreased the expression of PPARγ in cardiomyocytes. Notably, TGFβ significantly reduced the PPARγ mRNA level but not total protein level in cardiomyocytes ( Figure 5 ), suggesting that there were other downstream mediators of TGFβ present to mediate inhibitive regulation on PPARγ.
Dysfunction of the right ventricle has been recognized as an important contributing factor in heart disease. 34, 35 Right ventricle shortening is an independent predictor of survival in patients with advanced congestive heart failure. [36] [37] [38] [39] However, the mechanism involved in right ventricle dysfunction is still largely unknown. Our results identified the hypertrophic right ventricle in SM22-α-Nrp-1 KO mice, highlighting the cardiac protective role of NRP-1 in cardiomyocytes and SMCs for the first time. Meanwhile, the dysfunction of the right ventricle in SM22-α-Nrp-1 KO mice is more predominant than the left ventricle, as shown by the hypertrophic right ventricle in younger mice and the dilated right ventricle in older mice (Figure 2 ). These results suggest that increased afterload may be present, which leads to the observed hypertrophy and subsequent dilation of the right ventricle. No significant lung vascular remodeling and fibrosis were found; however, perivascular infiltration of inflammatory cells was found in older SM22-α-Nrp-1 KO mice where significant dilation of the right ventricle was observed (Figure 3) . Meanwhile, no significant difference in NRP-1 expression and the SM22-α-Cre expression pattern was present between the right ventricle and left ventricle (data not shown). This additionally suggests that a distinct NRP-1 signaling component may be involved between the right ventricle and left ventricle.
Recent studies have highlighted that metabolism in the heart contributes to systemic energy homeostasis. Resistance to high fat-induced obesity and insulin resistance has been achieved through the overexpression of MED13 or the inhibition of mir-208a in cardiomyocytes. 20 This increased cardiac energy expenditure was mediated through the regulation of several nuclear hormone receptors, including PPARγ, PGC1α, and thyroid receptor. 20 We also examined the expression of mir-208a in NRP-1 deleted cardiomyocytes and did not observe much difference compared with WT cardiomyocytes ( Figure XI in the online-only Data Supplement). Our results ( Figure 6 ) raised a possibility that signaling through cardiac NRP-1 is also essential for whole body metabolic homeostasis.
PGC1α is highly expressed in cardiomyocytes and acts as a central regulator of mitochondrial biogenesis and respiration. PGC1α knockout mice exhibit moderate cardiac defects with decreased ATP concentration and diminished cardiac function after hemodynamic and metabolic challenges. 40, 41 However, forced overexpression of PGC1α in cardiomyocytes was shown to increase mitochondria biogenesis but lead to death from heart failure with a stage-specific mechanism. 42, 43 Similarly, induced expression of PGC1α together with increased mitochondrial deposition and disorganized sarcomere structures were also observed in cardiac tissues of SM22-α-Nrp-1 KO mice (Figure 1) . Meanwhile, downstream effectors of PGC1α, including transcription factor B2M, medium-chain acyl-CoA dehydrogenase, etc, which mediate proliferation and respiration of mitochondria, were also induced in NRP-1 deleted cardiomyocytes. Metabolites analysis further confirm the increased tricarboxylic acid cycle activity in cardiac tissues of SM22-α-Nrp-1 KO mice ( Figure III in the online-only Data Supplement). These results suggested that increased level of PGC1α contributed to the abnormal mitochondrial accumulation in SM22-α-Nrp-1 KO hearts. However, we need to note that the mitochondrial accumulation in SM22-α-Nrp-1 KO heart was not as robust as previously reported in cardiac-specific PGC1α transgenic mice, 42, 43 which is probably because of the varying degree of PGC1α induction in SM22-α-Nrp-1 KO hearts and PGC1α transgenic hearts. Previous studies have shown that PPARγ expression is relatively low in cardiomyocytes. Cardiomyocyte-specific overexpression of PPARγ can lead to dilated cardiomyopathy Relative levels of 12,13-hydroxyoctadec-9(Z)-enoate (12,13-DHOME) and 9,10-hydroxyoctadec-12(Z)-enoic acid (9,10-DHOME) in the adipose tissues of WT and SM22-α-Nrp-1 KO mice. n=6 for each group. *P<0.05, **P<0.01, ***P<0.001.
with increased lipid and glycogen storage in mice. 44 We also evaluated the lipid accumulation in cardiac tissues of SM22-α-Nrp-1 KO mice. Although either total triglyceride or neural lipid was significantly altered (Figure X in the online-only Data Supplement), expression of carnitine palmitoyltransferase 1B, which acts as a downstream target of PPARγ and rate-limiting enzyme of fatty acid oxidation, was increased in cardiac tissues of SM22-α-Nrp-1 KO hearts ( Figure II in the online-only Data Supplement). Meanwhile, increased trends of free fatty acids, including linolenic, palmitic fatty acid, etc were observed in SM22-α-Nrp-1 KO hearts ( Figure X in the online-only Data Supplement). These results suggest that elevated expression of PPARγ was likely related to increased fatty acid oxidation. Although the role of increased fatty acid oxidation in cardiomyopathy is still not clear, many studies suggest a beneficial effect results from inhibiting fatty acid oxidation in heart failure, especially in ischemic heart failure. [45] [46] [47] [48] Similarly, we observed that SM22-α-Nrp-1KO mice were more vulnerable to ischemic stress ( Figure 3 ). These results suggest that increased PPARγ expression contributed to the cardiac phenotype in SM22-α-Nrp-1 KO mice. Previous studies have shown that PPARγ transgenic mice exhibited increased lipid accumulation at 8 months of age, and a significant increase in expression of PPARγ downstream targets was observed in MHC-PPARγ high but not in MHC-PPARγ low mice at 4 months old. 44 These findings suggest that the lipid toxicity effect of PPARγ is associated with its expression level and age, which partially explains the absence of increased lipid accumulation in SM22-α-Nrp-1 KO hearts. Furthermore, cardiomyocyte-specific knockout of PPARγ induced cardiac hypertrophy via increasing cardiac embryonic genes and activation of NFκB in mice. 49 Taken together, the literatures strongly suggest that normal levels of PGC1α and PPARγ are essential for optimal cardiomyocyte function. Our data reveal a novel role for NRP-1 as a negative regulator of PGC1α and PPARγ expression and is critical in maintaining normal cardiovascular health by balancing mitochondrial homeostasis, particularly under ischemia.
Many studies have documented reduced levels of PPARγ/ PGC1α in human and rodent heart failure, which are usually accompanied by a shift of utilization from fatty acid to glucose as an energy substrate and impaired mitochondrial biogenesis 50, 51 ; however, a few studies have also reported that unchanged or increased PGC1α is observed in conjunction with human heart failure. 52, 53 These studies suggested that the roles of PPARγ/PGC1α in failing hearts need to be evaluated with respect to severity and subtype of heart failure. Our results hereby showed that knockout of cardiac NRP-1 increased PPARγ/PGC1α expression and led to cardiomyopathy and aggravated ischemia induced heart failure, which will facilitate the elucidation of how endogenous PPARγ/PGC1α is regulated in cardiomyopathy and ischemic heart failure.
From a syndromic perspective, previous studies have implicated NRP1 in several disease modalities of the cardiovascular system including DiGeorge syndrome. 54 Genetic variations, specifically copy number variations, of NRP1 have been implicated in congenital heart disease. 55 Recently, a genomewide association study on Tetralogy of Fallot has suggested an association with a nonsynonymous single-nucleotide polymorphism rs2228638 located on the MAM (meprin/A5 protein/protein tyrosine phosphatase mu) domain in NRP1. 56 Pharmacogenomic traits (response to angiotensin II receptor blocker therapy) 57 and inflammatory biomarkers 58 were shown to be associated with the loci 10p12.1, close to the NRP1 locus (10p12). Childhood obesity-related traits in the Hispanic population were also mapped to a genomic region (10p12.1) near the NRP1 locus. 59 Emerging evidence suggests that apart from common variants, multiple rare variants of a gene in low frequency may affect complex diseases. 60 To examine the contribution of rare variants in NRP1 to heart, blood, or lung diseases, we compiled rare variants of NRP1 from the NHLBI GO Exome Sequencing Project Rare Variants for blacks and European-Americans and results are summarized in Figure  XII in the online-only Data Supplement. Deep resequencing of these regions with a large number of patient samples will be required to delineate the association of rare or common NRP1 variants with various cardiovascular, inflammatory, obesity, and pharmacogenomics-related traits.
In conclusion, our findings have identified the protective role of NRP-1 in cardiomyopathy and ischemia-induced heart failure and demonstrated that NRP-1 controls PGC1α and PPARγ expression and mitochondrial homeostasis through crosstalk with the Notch1 and Smad2 signaling pathways. Our results also have shown that NRP-1 in cardiomyocytes and SMCs contributes to systemic metabolism. These results provide potential therapeutic targets for cardiomyopathy and metabolic disorders.
